Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 5,11 € (-74,17 %). La mediana es de 5,11 € (-74,17 %).
| Comprar |
1 |
| Mantener |
0 |
| Vender |
0 |
Noticias Ir al feed de noticias
Yarrow Bioscience places share offering of about $150 million at $26 per share
Yarrow Bioscience has placed a public offering of 5,769,231 common shares at $26.00 per share, expected to raise approximately $150 million gross. The underwriting banks were granted a 30‑day option to purchase up to 865,384 additional shares; closing is expected on September 14, 2026. Net proceeds are intended primarily to fund research and development of the product pipeline, including the monoclonal antibody candidate YB‑101, and for general corporate purposes. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasDatos financieros de la empresa
| (EUR) | junio de 2026 | YoY |
|---|---|---|
| Ingresos | 84,99 mil | 45,18 % |
| Beneficio bruto | 79,74 mil | 36,20 % |
| Beneficio neto | -2,63 M | 46,04 % |
| EBITDA | -2,54 M | 47,90 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 186,1 M € |
Número de acciones | 9,3 M |
Máximo/mínimo de 52 semanas | 41,70 € - 14,21 € |
Rentabilidad por dividendo | 1,69 % |
Dividendos TTM | 0,35 € |
Beta | 2,07 |
Ratio P/E | -0,96 |
Ratio PEG | -0,01 |
Ratio P/B | 0,88 |
Ratio P/S | 434,72 |
Perfil de la empresa
| Nombre | Yarrow Bioscience |
| CEO | Rebecca Velez Frey |
| Empleados | 10 |
